Author(s): Jorge Felix, Valeska Andreozzi, Bjorn Vandewalle, et. al. EHA Library. Félix J. May 16, 2019; 267630 Abstract: PB2247 Session topic: 32. Platelets disorders Background Current guidelines recommend thrombopoietin receptor agonists (TPO-RAs: eltrombopag and romiplostim), splenectomy and rituximab as second-line treatment options for chronic immune thrombocytopenic purpura (ITP). To date no head-to-head...
Pro zobrazení tohoto obsahu je třeba být přihlášen.